Head-to-head evidence
SHR-1139 vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR-1139's landscape · tildrakizumab's landscape